Multiple Myeloma

Aou Citta' Della Salute E Della Scienza Di Torino

Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression

INVESTIGATING eNAMPT ROLE IN ACQUISITION OF EPITHELIAL TO MESENCHYMAL TRANSITION-LIKE FEATURES IN MULTIPLE MYELOMA

To strengthen preliminary data and to investigate the correlation between eNAMPT levels in BM and peripheral blood (PB) compartments by assessing its concentration in paired samples collected from a larger cohort of NDMM patients, using also more HDs as control.

To disclose eNAMPT relevance as potential marker of disease progression by comparing eNAMPT plasmatic levels from samples collected in different phases of disease (MGUS, Smoldering Multiple Myeloma -SMM-, NDMM, relapsed/refractory MM) and by their correlation with available clinical data.

To investigate cellular source of eNAMPT production in MM by analyzing both MM cells (Established Human Myeloma Cell Lines, HMCLs and primary CD138+ cells) and MM-BMSC compartment.

To investigate eNAMPT role in EMT features acquisition of HMCLs (with known molecular features such as karyotype status, mutations, drug-resistance phenotype etc.) and to define the underlying molecular mechanisms.

To determine the effects of previously identified neutralizing αeNAMPT antibody (Ab) (13) on MM cells both in vitro and in an in vivo MM-xenografted mouse model.

Dr. Alessandra Larocca

Principal Investigator

University of Turin, Italy

Categorized by 24-hr systolic BP (SBP): normotensive (< 125 mm Hg) on no BP medications

Categorized by 24-hr systolic BP (SBP): controlled hypertensive (< 130 mm Hg) on BP medication(s) and/or lifestyle modification

Categorized by 24-hr systolic BP (SBP): uncontrolled hypertensive (≥ 130 mm Hg) on 0-2 BP medications

Categorized by 24-hr systolic BP (SBP): hypertensive (≥ 135 mm Hg) resistant to 3 or more BP medications ideally including a diuretic (resistant hypertension)

As a part of the research protocol, we intend to draw from each participant at baseline and following 4 months of PAP therapy. All samples will be processed according to the recommended procedures for the different analyses we intend to measure and stored at -80°C until analysis.

Sleep Apnea, Obstructive

Hypertension

Participants will use Positive Airway Pressure (PAP) treatment

Positive Airway Pressure

University of Pennsylvania

University of Iceland

Mechanisms for Individual Differences in Hypertension in Obstructive Sleep

Measured using 24-hour ambulatory blood pressure monitoring

National Institutes of Health (NIH)

National Heart, Lung, and Blood Institute (NHLBI)

Larynx Cancer

Free University Medical Centre Amsterdam

Rijnstate Ziekenhuis Arnhem

Academic Hospital Maastricht

Radboud University Nijmegen Medical Centre

Universitair Medisch Centrum Utrecht

Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas

Patient Selection for Hypoxia Modifying Treatments Based on Functional Microregional Imaging of Tumor Vasculature, Oxygenation and Proliferation in Squamous Cell Carcinoma of the Larynx

nicotinamide/hypoxia

Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression

Mechanisms for Individual Differences in Hypertension in Obstructive Sleep

Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu